Related Experiment Video
Updated: Jan 25, 2026
09:58
Pharmacological and Functional Genetic Assays to Manipulate Regeneration of the Planarian Dugesia japonica
Published on: August 31, 2011
37.6K
Pharmacological development in hidradenitis suppurativa
Łukasz Matusiak1, Gregor Be Jemec2, Jacek C Szepietowski1
1Department of Dermatology, Venereology and Allergology, Medical University, Wroclaw, Poland.
Current Opinion in Pharmacology
|May 11, 2019
Summary
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. While treatments are improving, new biologics targeting inflammatory pathways offer hope for effective therapy.
Area of Science:
- Dermatology
- Immunology
- Inflammatory Diseases
Background:
- Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory skin condition.
- HS presents with nodules, abscesses, and suppurating lesions, causing significant debilitation.
- Despite recent treatment advancements, effective therapy for HS remains a challenge.
Purpose of the Study:
- To review current understanding of HS pathogenesis.
- To discuss emerging therapeutic strategies targeting specific inflammatory pathways.
- To highlight the role of cytokine blockade in HS management.
Main Methods:
- Review of current literature on HS pathogenesis and treatment.
- Analysis of the role of cytokines (TNF-a, IL-1, IL-17, IL-23) in HS.
- Examination of ongoing clinical trials for new biologic agents.
Main Results:
- Current HS treatments target hyperkeratinization, pilosebaceous occlusion, dysbiosis, and inflammation.
- Cytokine blockade, particularly TNF inhibition, is a key therapeutic approach.
- Adalimumab is the only approved biologic; several new agents are in development.
Conclusions:
- Targeting specific inflammatory pathways with biologics represents a promising future for HS treatment.
- New agents like bermekimab, bimekizumab, guselkumab, secukinumab, and IFX-1 are under investigation.
- Further research and clinical trials are crucial for advancing HS management.
More Related Videos
Related Concept Videos
01:28Cholinergic Antagonists: Pharmacological Actions
1.7K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.7K
01:15Drug Abuse and Addiction: Pharmacological Phenomena
1.2K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.2K
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
729
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
729
01:29Inflammatory Bowel Disease IV: Pharmacological Management
556
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
556
01:25Factors Influencing Drug Absorption: Disease States and Pharmacology
1.4K
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
1.4K
00:59Direct-Acting Cholinergic Agonists: Pharmacological Actions
2.3K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
2.3K